Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | MAP kinase-activated protein kinase 2 | ||
Ligand | BDBM50336316 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_471134 (CHEMBL921287) | ||
IC50 | >10000±n/a nM | ||
Citation | Mulvihill, MJ; Ji, QS; Coate, HR; Cooke, A; Dong, H; Feng, L; Foreman, K; Rosenfeld-Franklin, M; Honda, A; Mak, G; Mulvihill, KM; Nigro, AI; O'Connor, M; Pirrit, C; Steinig, AG; Siu, K; Stolz, KM; Sun, Y; Tavares, PA; Yao, Y; Gibson, NW Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem16:1359-75 (2008) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
MAP kinase-activated protein kinase 2 | |||
Name: | MAP kinase-activated protein kinase 2 | ||
Synonyms: | MAP kinase-activated protein kinase 2 (MAPKAPK2) | MAP kinase-activated protein kinase 2 (MK2) | MAP kinase-activated protein kinase 2 (p38/MK2) | MAPK-Activated Protein Kinase 2 (MK2) | MAPK-activated protein kinase 2 | MAPK2_HUMAN | MAPKAP kinase 2 | MAPKAPK-2 | MAPKAPK2 | MK2 | ||
Type: | Serine/threonine-protein kinase | ||
Mol. Mass.: | 45579.87 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P49137 | ||
Residue: | 400 | ||
Sequence: |
| ||
BDBM50336316 | |||
n/a | |||
Name | BDBM50336316 | ||
Synonyms: | CHEMBL410659 | cis-3-(3-(azetidin-1-ylmethyl)cyclobutyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine | cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine | ||
Type | Small organic molecule | ||
Emp. Form. | C29H28N6 | ||
Mol. Mass. | 460.5728 | ||
SMILES | Nc1nccn2c(nc(-c3ccc4ccc(nc4c3)-c3ccccc3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |wU:26.30,28.33,(7.04,-25.52,;7.05,-27.06,;5.72,-27.83,;5.72,-29.37,;7.05,-30.15,;8.39,-29.37,;9.86,-29.85,;10.77,-28.6,;9.86,-27.34,;10.64,-26.02,;9.88,-24.69,;10.64,-23.36,;12.19,-23.36,;12.96,-22.02,;14.5,-22.04,;15.28,-23.37,;14.5,-24.71,;12.96,-24.7,;12.18,-26.03,;16.82,-23.38,;17.59,-24.72,;19.13,-24.72,;19.9,-23.38,;19.12,-22.05,;17.59,-22.05,;8.39,-27.82,;10.34,-31.32,;9.65,-32.69,;11.02,-33.38,;11.5,-34.85,;10.47,-35.99,;8.93,-36.07,;9.01,-37.61,;10.55,-37.53,;11.72,-32.01,)| | ||
Structure |